SEC Form 4 · accession 0001171843-16-008385
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Lichtlen
Officer — Chief Medical Officer
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $13.80 | Mar 2, 2016 | A | 44,000 | A | — | Mar 2, 2026 | Class A Common Stock | 44,000 | 269,400 | D |
Explanation of responses
- F1The option vests in 4 equal annual installments beginning on March 2, 2017